Add Yahoo as a preferred source to see more of our stories on Google. The Amgen logo is seen in this illustration taken August 3, 2025. REUTERS/Dado Ruvic/Illustration May 15 (Reuters) - At ‌least 20 ...

Japanese drugmaker Kissei Pharmaceutical 4547-6.85%decrease; down pointing triangle said doctors in Japan can again prescribe an Amgen AMGN-0.64%decrease; down pointing triangle rare-disease drug to ...

Twenty people died in Japan after receiving Tavneos, a rare disorder therapy developed by Amgen (AMGN), prompting its local partner Kissei (KSPHF) to urge healthcare professionals to exercise caution ...

A Japanese pharmaceutical firm has warned doctors against prescribing a drug for rare autoimmune diseases to new patients following the deaths of 20 people who took it. Kissei Pharmaceutical, which ...

Kissei Pharmaceutical has revised a package insert in Japan for Amgen's rare immune-disease drug Tavneos, saying that serious liver dysfunction could occur. The Japanese pharmaceutical company said ...

Amgen is standing behind a rare disease drug that the FDA wants off the market due to safety concerns and alleged clinical trial manipulation, and its defense will include a new analysis of the ...

June 29 (Reuters) - The New England Journal of Medicine on Monday retracted an article on a pivotal clinical trial that supported approval of Amgen’s (AMGN.O), opens new tab rare-disease drug, citing ...

The European Medicines Agency (EMA) has recommended that marketing authorisation for Tavneos (avacopan) be revoked due to question marks over the integrity of clinical data used to support its initial ...

June 26 (Reuters) - Europe's drug regulator on Friday recommended revoking the marketing authorization for Amgen's rare autoimmune disease medicine, citing concerns over the integrity of its trial ...

July 24 (Reuters) - Amgen said on Friday it submitted new evidence to the FDA on July 23 as it seeks a hearing to challenge the proposed withdrawal of its rare-disease drug Tavneos from the U.S.